Objective: There are conflicting reports about outcomes after infrainguinal bypass for chronic limb-threatening ischemia (CLTI) in patients with diabetes. We compared perioperative outcomes between patients with and patients without diabetes in the current era.
Results:
We identified 8887 patients undergoing open (5744; 50% diabetic) or endovascular (3143; 62% diabetic) treatment for CLTI. Patients with diabetes were younger and more often nonwhite, nonsmokers, and obese. Patients with diabetes presented more often with tissue loss (71% vs 47%; P < .001) and were more likely to be treated with endovascular intervention (41% vs 29%; P < .001). ; however, these differences were no longer significant after adjustment for baseline differences. Patients with diabetes had a higher rate of MACEs (7.0% vs 5.1%; P < .01) and lower rate of MALEs (8.1% vs 10%; P < .01) after bypass. After adjustment, patients with diabetes still had a lower rate of MALEs (OR, 0.7; 95% CI, 0.6-0.9) but no longer had a higher rate of MACEs (OR, 1.2; 95% CI, 0.9-1.6).
Conclusions: CLTI patients with diabetes undergoing revascularization have similar 30-day outcomes compared with those without diabetes, although they appear to be at lower risk for MALEs after bypass. Prolonged length of stay and readmission in patients with diabetes is not due to underlying diabetic disease but likely secondary to other baseline comorbidities, such as higher rates of tissue loss. Concern for worse perioperative outcomes in patients with diabetes after lower extremity bypass is unsubstantiated and should not discourage a physician from performing an open bypass. (J Vasc Surg 2018; 68:487-94.) Management of patients with diabetes mellitus and chronic limb-threatening ischemia (CLTI) is challenging, given the associated comorbidities and anatomic pattern of distal atherosclerotic vascular disease. [1] [2] [3] [4] It is estimated that up to 25% of diabetic patients develop a foot ulcer during their lifetime, with rates of amputation 15 to 30 times higher than in nondiabetic patients. [5] [6] [7] Although patients with diabetes have a high prevalence of disease burden in the infrapopliteal arteries, bypass to a patent distal tibial or pedal artery can be a durable revascularization option for limb salvage. 8, 9 These operations had been the standard of care before the advent of endovascular therapy, which today is often used as first-line therapy. [10] [11] [12] [13] There have been conflicting reports about the outcomes after lower extremity revascularization between patients with and patients without diabetes. A prior study from our institution found no differences in late mortality, graft patency, and limb salvage rates of patients with and without diabetes after open bypass.
14 However, other reports have identified higher rates of amputation, graft failure, and even mortality after lower extremity bypass in patients with diabetes. [15] [16] [17] Therefore, the purpose of this study was to use a national multi-institutional registry to evaluate perioperative differences in outcomes of patients with and without diabetes who underwent lower extremity intervention for CLTI, with either bypass or endovascular techniques, in the current era.
METHODS
Data set. Using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) vascular surgery targeted module from 2011 to 2014, we identified all patients undergoing infrainguinal revascularization by either open or endovascular intervention. Open intervention included infrainguinal bypass and endarterectomy procedures. The NSQIP is a multiinstitutional collaboration that uses trained clinical reviewers to collect preoperative, intraoperative, and 30-day outcome data on eligible procedures at participating hospitals. These trained clinical reviewers use a combination of electronic chart review and rigorous 30-day follow-up with phone calls to patients if necessary to incur complete data collection. For lower extremity revascularization, hospitals are self-selected to participate in the targeted NSQIP modules for endovascular and bypass interventions separately; however, recent studies have identified similar outcomes among hospitals participating in the targeted and nontargeted NSQIP modules. 18 Additional information on the NSQIP is available at www.facs.org/quality-programs/acs-nsqip.
Patients and cohort. We identified 13,678 patients undergoing lower extremity revascularization in the targeted NSQIP module. Patients undergoing intervention who had no symptoms (n ¼ 510), claudication (n ¼ 4092), or no documentation of symptoms (n ¼ 189) were excluded, leaving 8887 for analysis. These remaining CLTI patients therefore included those with rest pain and tissue loss. Patients were further grouped into those with documented diabetes mellitus (insulin dependent or noninsulin dependent) and those without diabetes. The insulin-dependent group (n ¼ 3139) consisted of patients with a diagnosis of diabetes treated with daily insulin therapy in the outpatient setting before hospitalization or the index procedure. Admitted patients who were switched from oral agents to insulin sliding scale were not considered insulin dependent. The noninsulin-dependent group (n ¼ 1654) included patients taking noninsulin antidiabetic oral medications only. Patients were also grouped into those who underwent bypasses using single-segment saphenous vein and those who underwent bypasses using prosthetic, spliced vein, or composite conduits.
All variable definitions captured by the NSQIP are standardized for accurate and reliable collection by clinical reviewers and can be found at www.facs.org/qualityprograms/acs-nsqip.
New or aggregate variables used in this analysis included obesity, defined as a body mass index >30. Elevated baseline creatinine concentration was captured as a binary variable for creatinine value >1.4 mg/dL. Congestive heart failure included a new diagnosis in the past 30 days or an exacerbation before revascularization. Wound classification was divided into clean vs contaminated. Contaminated wound class included wounds documented as clean/contaminated, contaminated, or dirty/infected.
All outcomes were within 30 days of the index operation. Myocardial infarction was diagnosed on electrocardiography or by documentation stating a diagnosis of myocardial infarction. A major adverse cardiovascular event (MACE) was defined as myocardial infarction, stroke, or cardiac arrest. A major adverse limb event (MALE) was defined as major amputation or operative reintervention in the treated vessel. Reinterventions included new or revision lower extremity bypass of the same limb, jump or interposition graft revision, bypass graft thrombectomy, thrombolysis, or endovascular reintervention of a treated arterial segment. mortality, MACE, MALE, prolonged length of stay, readmission, and surgical site infection. Prolonged length of stay was defined as >75th percentile of study patients. Purposeful selection, which uses both univariate screen (using a P < .1 cutoff) and previously identified predictors for the end point of interest, was used to initially populate these models. 19 The Hosmer-Lemeshow statistic for goodness of fit was used to assess the multivariable models. Emergent cases were excluded in the multivariable models because the nature of emergent presentations could overshadow the effect of diabetes. All tests were two sided, and P < .05 was considered statistically significant. SPSS Statistics version 22.0 (IBM Corp, Armonk, NY) was used for all analyses. Permission to use deidentified data from the NSQIP, without the need for informed consent, was obtained from the Institutional Review Board at Beth Israel Deaconess Medical Center.
RESULTS
Of the 8887 patients undergoing intervention for CLTI, 4793 interventions were performed in patients with diabetes (54%), whereas 4094 were performed in patients without diabetes (46%; Table I ). The majority (65%; n ¼ 3139) of patients with diabetes were insulin dependent. Patients with diabetes presented more often with tissue loss (vs rest pain) compared with patients without diabetes (71% vs 47%; P < .001).
Demographics and comorbidities. The two groups had significant differences with regard to age, race, comorbidities, and preoperative medications (Table I) . Patients with diabetes were younger (68 vs 70 years; P < .001) and less often white (64% vs 71%; P < .001). Patients with diabetes were more likely to have hypertension (90% vs 78%; P < .001), obesity (38% vs 20%; P < .001), and congestive heart failure (4.8% vs 3.1%; P < .001). They were also more likely to present with sepsis (6.7% vs 4.4%; P < .001) and to have a documented open wound or infected wound (59% vs 39%; P < .001). Patients with diabetes were also more likely to have baseline renal dysfunction as reported with elevated baseline creatinine concentration (36% vs 20%; P < .001) and dialysis dependence (13% vs 7.0%; P < .001), and they were more likely to have a dependent functional status before the operation (14% vs 8.8%; P < .001). Patients with diabetes were less likely to be current smokers (29% vs 43%; P < .001) and to have a diagnosis of severe chronic obstructive pulmonary disease (9.8% vs 14%; P < .001). There was no significant difference in sex distribution between the two groups (61% vs 60% male; P ¼ .23).
Patients with diabetes were more likely to have a prior endovascular intervention (21% vs 17%; P < .001) and less likely to have a prior bypass procedure (18% vs 25%; P < .001). Preoperatively, patients with diabetes were more likely to be taking an antiplatelet (83% vs 77%; P < .001) and beta blocker medication (70% vs 57%; P < .001) but less likely to be taking a statin medication (60% vs 76%; P < .001).
Operative details. Of the 8887 patients, 5744 of the patients (65%) underwent open lower extremity bypass and 3143 (35%) underwent endovascular intervention. Patients with diabetes were more likely to be treated with endovascular intervention (41% vs 29%; P < .001), regardless of presentation with rest pain (34% vs 28%; P < .001) or tissue loss (43% vs 31%; P < .001).
Patients with diabetes undergoing bypass were more likely to be treated for tissue loss (68% vs 46%; P < .001) compared with patients without diabetes. The most common type of bypass performed overall was femoral-tibial/pedal bypass (diabetes, 50%; no diabetes, 54%), followed by femoral-popliteal bypass (diabetes, 33%; no diabetes, 34%; Table II ). Patients with diabetes were more likely to have isolated below-knee disease treated (popliteal-tibial/pedal bypass, 14% vs 7.7%; P < .001). Patients with diabetes were less likely to have bypasses performed for emergent situations (5.6% vs 8.6%; P < .001). In both groups, the majority of operations had clean, noncontaminated operative fields.
Patients with diabetes undergoing endovascular lower extremity intervention were more likely to be treated for tissue loss (75% vs 50%; P < .001). They were also more likely to be treated for tibial disease (31% vs 23%; P < .001) and less likely to have emergent endovascular interventions (4.4% vs 7.6%; P < .001; Table V) .
Patients with diabetes undergoing bypass had an increased rate of MACE (7.0% vs 5.1%; P < .01) on univariate analysis but not after adjustment (OR, 1.2; 95% CI, 0.9-1.6). Adjusted variables included age, CLTI type (rest pain, tissue loss), anatomic location of intervention, race (white, nonwhite), sex, smoking status, obesity, chronic obstructive pulmonary disease, congestive heart failure, elevated baseline creatinine concentration, dialysis, preoperative sepsis, prior bypass, and prior endovascular procedure. However, patients with diabetes undergoing bypass were at lower risk for MALEs (8.1% vs 10%; P < .01) even after adjustment (OR, 0.7; 95% CI, 0.6-0.9). Rates of 30-day major amputation were similar between the two groups (4.7% vs 4.7%; P ¼ .99); however, patients with diabetes had a lower 30-day reintervention rate (4.5% vs 6.7%; P < .001). Untreated patency loss was similar in both groups (2.4% vs 2.9%; P ¼ .22). Patients with diabetes presenting with rest pain and without tissue loss had a lower rate of MALEs compared with patients without diabetes (OR, 0.6; 95% CI, 0.4-0.9). However, excluding patients with rest pain, differences were no longer found for MALEs (OR, 0.9; 95% CI, 0.7-1.1) in patients presenting with tissue loss. There was no difference in MALEs after endovascular intervention between patients with and patients without diabetes (9.2% vs 9.8%; P ¼ .55; OR, 1.1; 95% CI, 0.9-1.3).
Patients Patients were stratified by bypass conduit type on the basis of whether single-segment saphenous vein was used. Those who did not have single-segment saphenous vein conduit instead underwent bypass with prosthetic, spliced vein, or composite conduits. No differences in outcomes were found between patients with diabetes and patients without diabetes undergoing bypass with prosthetic, spliced vein, or composite conduit in terms of 30-day mortality (OR, 1.0; 95% CI, 0.6-1.7), MACE (OR, 1.0; 95% CI, 0.7-1.5), or MALE (OR, 0.8; 95% CI, 0.6-1.1). In patients undergoing bypass with single-segment saphenous vein, no differences were seen for 30-day morality (OR, 1.1; 95% CI, 0.6-1.8) or MACE (OR, 1.4; 95% CI, 0.96-1.0). However, lower rates of MALE were found in patients without diabetes (OR, 0.7; 95% CI, 0.5-0.9), and this difference again was driven by lower rates of major reintervention (4.0 vs 7.4; P < .001). 
DISCUSSION
Patients with diabetes and CLTI who undergo infrainguinal revascularization have similar 30-day mortality compared with patients without diabetes, after both bypass and endovascular intervention. Patients with diabetes appear to be at lower risk of MALEs within Only nonemergency cases were used in the models. Predicted probabilities and CIs for both open infrainguinal bypass and endovascular intervention models are adjusted for diabetes, age, CLTI type (rest pain, tissue loss), anatomic location of intervention, race (white, nonwhite), sex, smoking status, obesity, chronic obstructive pulmonary disease, congestive heart failure, elevated baseline creatinine concentration, dialysis, preoperative sepsis, prior bypass, and prior endovascular procedure. Bolded P values indicate statistically significant findings with P <.05. In addition, these studies focus on long-term outcomes. This current study instead uses multi-institutional 30-day outcome data, thereby providing stronger supporting evidence that diabetes also does not negatively influence short-term outcomes after infrainguinal bypass. Despite these findings, several other studies have suggested that diabetic patients have less successful outcomes after infrainguinal bypass. They have shown through single-center and multi-institutional review that diabetic patients have higher rates of graft failure, amputation, and mortality after open infrainguinal bypass for both long-and short-term follow-up. CallePascual et al 15 reported a 3-year series of 588 bypasses performed in a single center and found that diabetic patients had lower limb salvage rates for both femoralpopliteal (49% vs 90%; P < .001) and femoral-tibial/ pedal (74% vs 95%; P < .01) bypasses. Analysis of 1840 patients in the Swedish vascular registry showed that the incidence of ipsilateral major amputation or death was higher in patients with diabetes after 2-year followup, even after adjustment for baseline differences (hazard ratio, 1.46; 95% CI, 1.26-1.69). 16 Using the Finland national vascular registry, which consisted of 5709 operations for CLTI, Virkkunen et al 17 concluded that diabetes in the short term is associated with higher 30-day below-knee amputation rates (6.5% vs 3.3%; P < .001).
These conflicting results among single-center and single-surgeon reports may be due to differences in individual practice patterns. However, differences found in the multi-institutional, national registry studies are more difficult to elucidate. Whereas the Swedish and Finnish national registries examined interventions performed between the years 1991 and 1999 and 2001 and 2003, respectively, this current study reviews outcomes in interventions performed in the years 2011 to 2014. During this time, changes in diabetes management, medical practice patterns, and popularity of endovascular therapy may have influenced outcomes. The racial and ethnic distribution of our study populations is also different. Whereas the Swedish and Finnish populations consist of a more homogeneous makeup, the U.S. population represents a more diverse demographic, with a larger proportion of Hispanic and African American patients. In this study, only 64% of the diabetic patients were white.
Analyzing outcomes from other U.S. national database studies can help clarify these population-based differences. A study of 1977 infrainguinal bypasses from 2003 to 2010 within the Vascular Study Group of New England (VSGNE) concluded that diabetes was not associated with in-hospital mortality but was associated with increased major adverse events, which was a composite outcome of myocardial infarction, dysrhythmia, congestive heart failure, wound infection, renal insufficiency, and major amputation. 21 We similarly noted higher rates of myocardial infarction on univariate analysis for patients with diabetes but not after adjustment for baseline differences. Our results differ from those in the VSGNE study in that we found no differences in major amputation or wound infection rates. These differences may be attributable to postdischarge complications, which may be better captured in the NSQIP because of its nearly complete evaluation of 30-day outcomes including postdischarge information, whereas the VSGNE database is limited to information that occurs within a patient's index admission. Our group previously reviewed 6565 patients undergoing major vascular operations, including lower extremity, carotid, and aortic procedures, in an effort to clarify the risk associated with diabetes. 22 We reported that patients with diabetes had lower perioperative mortality; however, their 5-year survival was significantly worse. In bypass patients, diabetes was not independently associated with perioperative mortality. Instead, history of congestive heart failure and hemodialysis were factors contributing to perioperative morality. Despite the lack of association between diabetes and poor perioperative outcomes, this analysis of the NSQIP database revealed that patients with diabetes were more likely to be treated with endovascular therapy compared with those without diabetes. This may reflect an unsubstantiated concern that patients with diabetes have inferior outcomes after lower extremity bypass, although other factors, such as inadequate length of autologous vein for tibial or pedal bypasses, will also influence a surgeon's preference for more aggressive endovascular intervention. Interestingly, we found that lower rates of MALEs in patients with diabetes were attributable to lower rates of 30-day reinterventions without higher rates of untreated patency loss. This finding may be explained by preferential selection for bypass in patients with more favorable anatomy and available autologous vein, thereby resulting in higher patency. Alternatively, smoking rates are higher in patients without diabetes, and continued smoking after lower extremity bypass is associated with increased graft failure. 23 The major limitations of this study are inherent to studies using the NSQIP registry, which was originally designed as a quality improvement tool to compare individual institutional outcomes with aggregated national outcomes. Although the vascular targeted module allows analysis of more specific vascular surgery variables, the database is still not completely comprehensive of all patient characteristics and intraoperative and postoperative variables. Notable variables were missing or poorly recorded that would have been helpful for this analysis. These include ankle-brachial and toe-brachial indices; Wound, Ischemia, and foot Infection classification; and TransAtlantic Inter-Society Consensus classification. In addition, reviewers in the NSQIP registry are limited to selecting either femoral-popliteal or tibial intervention after lower extremity endovascular interventions, so it is unclear how many patients had multilevel intervention. NSQIP outcomes are also limited to 30-day events. Complications after revascularization can evolve and develop during longer periods and would not be captured in this study, such as long-term patency, delayed reintervention, major amputation, wound healing, and death. Last, there was no randomization between treatment options. The selection of endovascular intervention vs bypass was left to the treating physician's discretion.
CONCLUSIONS
In this large clinical registry, patients with and without diabetes undergoing bypass or endovascular intervention for CLTI have similar perioperative outcomes. Given these results, we believe the treating physician should not be discouraged from performing a bypass on an appropriately selected patient with diabetes but instead should use the same criteria as would be used for a patient without diabetes to make this decision.
